Acepodia Partners with Pfizer to Advance Antibody-Cell Conjugation Therapies in Autoimmune Diseases
Wednesday, September 04, 2024
Acepodia has announced a partnership with Pfizer Ignite to advance the exploration of innovative treatment options for autoimmune diseases.
Functioning in a holistic fashion, Pfizer Ignite takes advantage of the broad range of resources, expertise and experienced involved in drug development at Pfizer so as to assist biotech firms with their inventions from inception all through clinical trial stages till it becomes an approved product.
Additionally, as part of this partnership, Pfizer Ignite will guide Acepodia strategically in its quest towards more advanced stages of cell therapy meant for both tumor diseases as well as other immune disorders.
Under the conditions of this agreement, Acepodia shall hold complete authority with regard to its programme’s advancement and future partnerships as well.
In this partnership, Acepodia would be able to utilize Pfizer’s extensive R&D capabilities in order to improve clinical trial design, regulatory strategies and develop novel drugs. One of the goals of the Pfizer Ignite initiative is to provide assistance in creating new treatments that would meet unmet needs while also aligning them with the company’s priorities addressed by strategic grounds.
Acepodia is thrilled at the prospect of working together with Pfizer in order to convert their promising scientific platform into new therapies for those who are waiting for cure.
Following this agreement, it is Acepodia that has complete control over future partnership opportunities as well as progress of its programme.
The system is structured in such a way as to allow for greater scalability while preventing severe adverse events related to CAR-T therapy like cytokine release syndrome or neurotoxicity among others. The leading clinical candidate at Acepodia – ACE1831 is currently being compared against phase I've human trials for individuals afflicted with non-Hodgkin's lymphoma that have been marked by long-lasting effects after even one dose given with minimal levels used at that time Point.
The plan for expanding this platform therefore appears more viable and avoids those much-feared negative side effects like cytokine storm or neurotoxicities often associated with CAR-Ts. In Acepodia’s collection is ACE1831, currently in its first human trial for non-Hodgkin's lymphoma which conveys only a strong constant impact after being given just once at the least possible dosage.
Autoimmune diseases represent gigantic unmet needs, and although CAR-T treatments have shown initial promise, using them on a regular basis in cases of autoimmune diseases has proven difficult.
The ACC platform from Acepodia can deliver all the advantages attributed to CAR-T treatment without these hurdles while our alliance with Pfizer Ignite will assist us to provide these immunotherapies to patients desperately seeking alternative care options.
Source: prnewswire.com
